Copyright: ©Author(s) 2026.
World J Gastroenterol. Oct 7, 2026; 32(37): 119668
Published online Oct 7, 2026. doi: 10.3748/wjg.119668
Published online Oct 7, 2026. doi: 10.3748/wjg.119668
Table 4 Overall summary of adverse events (intention-to-treat set), n (%)
| Variable | 7-day PC-BMT (n = 119) | 14-day PC-BMT (n = 118) | 14-day P-BMT (n = 117) | |||
| n | Frequency | n | Frequency | n | Frequency | |
| Adverse event | 23 (19.3) | 34 | 36 (30.5) | 51 | 32 (27.4) | 40 |
| 95%CI | 12.7-27.6 | 22.4-39.7 | 19.5-36.4 | |||
| P value | 0.145 | 0.594 | ||||
| Drug-related adverse event | 23 (19.3) | 34 | 35 (29.7) | 50 | 31 (26.5) | 39 |
| 95%CI | 12.7-27.6 | 21.6-38.8 | 18.7-35.5 | |||
| P value | 0.190 | 0.589 | ||||
| Serious adverse event | 0 | 0 | 0 | 0 | 0 | 0 |
- Citation: Oh CK, Lim H, Noh JH, Gong EJ, Seo SI, Bang CS, Kim YJ, Shin WG, Kim JB, Jang HJ, Baik GH. Efficacy of 7-day and 14-day potassium-competitive acid blocker-based bismuth-containing quadruple regimen for Helicobacter pylori infection. World J Gastroenterol 2026; 32(37): 119668
- URL: https://www.wjgnet.com/1007-9327/full/v32/i37/119668.htm
- DOI: https://dx.doi.org/10.3748/wjg.119668